8 results
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
Primary objective1. To investigate whether TM38837 attenuates the central effects of THCSecondary objectives2. To explore the effect of TM38837 on THC induced effects on heart rate3. To investigate the effect of 60 mg rimonabant on THC-induced CNS…
Primary Objective:* To investigate the effects of THC on fMRI activation patterns in healthy volunteersSecondary objective:* To assess the feasibility of pharmacokinetic/pharmacodynamic (PK/PD)-analyses for THC-induced fMRI-activation patterns* To…
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
Assess the effect of 2 doses (10 and 20 mg) dronabinol on driving performance compared to placebo in light and heavy cannabis users. The heavy users are used as a model for chronic use of dronabinol.
Primary objective: Our key objective is to determine if a cannabinoid manipulation is more effective than a glucocorticoid manipulation to facilitate fear memory extinction retention in an experimental model of exposure therapy in healthy…
Primary Objective:• To evaluate the safety and tolerability of danavorexton single IV infusion administered in healthy subjects undergoing OIRD.Secondary Objective:• To assess the PK of danavorexton single IV infusion administered in healthy…